European best practice guidelines 17-18: Adverse effects

Nephrology Dialysis Transplantation

Volumn 15, Issue SUPPL. 4, 2000, Pages 51-56

  Horl, W H ^a   Jacobs, C ^a   Macdougall, I C ^a   Valderrabano, F ^a   Parrondo, I ^a   Carveth, B G ^a   Thompson, K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HEMOGLOBIN; HEPARIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANTIHYPERTENSIVE THERAPY; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; HEALTH SURVEY; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOSIS; VASCULAR ACCESS;

EID: 0033815511     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.suppl_4.51     Document Type: Article

References (5)

1. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin
2. Vascular access thrombosis during recombinant human erythropoietin therapy
3. Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients
4. Vascular access thrombosis in new hemodialysis patients
5. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin